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Abstract
Cryopyrin-associated periodic syndromes (CAPSs) are a growing family of autoinflammatory diseases, also known 
as periodic fever syndromes. There are three forms of CAPS: (1) Familial Cold autoinflammatory syndrome or familial 
cold urticaria, (2) Muckle-wells syndrome, and (3) neonatal-onset multisystem inflammatory disease or chronic 
infantile neurological cutaneous articular syndrome. Genetic mutations in the NLRP3 gene were found to be present 
in most patients. The foremost common findings between all the CAPS disorders are rash, fever which is sometimes 
present at birth or in early childhood, joint problems, and conjunctivitis. More extreme forms of CAPS include more 
persistent inflammation that can cause hearing loss and meningitis and can lead to mental and developmental 
delays. Drugs for CAPS target the source of inflammation – which is the over-production of interleukin 1ß by modified 
cryopyrin inflammasomes. Three drugs are used to treat CAPS: Rilonacept, canakinumab, and anakirna. With these 
drugs, the prognosis is greatly improved, with most patients having less frequent episodes, decreased buildup of 
amyloid in the body, and extended life of severe cases up to adulthood.
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Introduction
Cryopyrin-associated periodic syndromes 
(CAPSs) are a growing family of autoinflammatory 
diseases, also known as periodic fever syndromes. 
Autoinflammatory diseases are a group of disorders 
characterized by repetitive episodes of systemic and 
organ-specific inflammation. Unlike autoimmune 
diseases which are caused by activation of the 
specific immune system, people with autoinflammatory 
diseases do not produce autoantibodies or antigen-
specific lymphocytes, instead, these diseases are 
caused by genetic mutations in molecules that regulate 
the innate immune response [1], [2]. There are three 
forms of CAPS: (1) Familial cold autoinflammatory 
syndrome (FCAS) or familial cold urticaria, (2) Muckle-
Wells Syndrome (MWS), and (3) Neonatal-onset 
multisystem inflammatory disease (NOMID) or chronic 
infantile neurological cutaneous articular syndrome 
(CINCA). Genetic mutations in the NLRP3 gene were 
found to be present in most patients [3], [4], [5], [6]. 
These three syndromes represent varying degrees 
of inflammation caused by the same condition with 
different levels of severity. The NLRP3 gene gives 
instructions for making a protein called cryopyrin which 
is one of the regulators of the process of inflammation. 
Cryopyrin is included within the get together of a 
molecular complex called an inflammasome that 
mediates activation of caspase-1. Caspase-1 regulates 
the production of interleukin-1 (IL-1) beta. NLRP3 
mutations result in an abnormal cryopyrin structure, 
leading to abnormally high inflammasome activity 
response, resulting to overproduction of proinflamatory 
cytokine IL-1ß [3], [4], [5], [6], [7], [8], [9]. These results 
are connected with the episodes of fever and damage 
to the body’s cells and tissues. The foremost common 
findings between all the CAPS disorders are rash, fever 
which is sometimes present at birth or in early childhood, 
joint problems, and conjunctivitis. More extreme forms 
of CAPS include more persistent inflammation that 
can cause hearing loss and meningitis and can lead to 
mental and development delays.
Epidemiology
CAPS is very rare diseases. The incidence in 
Germany is 0.34 per 106 persons-years [10]. Based on 
that, research in Republic of Macedonia should be 1–2 
new patients every 2 years.
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FCAS
This disorder has autosomal dominant 
inheritance, and genetic mutation is on the NLRP3 gene. 
Most of the patients with FCAS can have a normal life 
and have children so they can pass the genetic mutation 
through generations. Characteristics of the disorder are 
recurrent episodes of fever and rash that occurs 1–2 h after 
exposure to cold temperature. The start of the disease is 
under 6 months of age, or sometimes in early childhood. 
Some patients have a rash display at birth. Many patients 
have rash each day, but seriously attacks happened 
after exposure to cold temperature. Sometimes after the 
occurrence of the rush, there is elevated temperature 
and arthralgia. Some patients also have abdominal pain, 
conjunctivitis, sweating, and headache. The duration of the 
episodes is less or around 24 h. Treatment incorporates 
warming of the patient, non-steroid anti-inflammatory 
drugs, corticosteroids, and IL-1 blocking agents to prevent 
cellular uptake of IL1 ß [4], [11].
MWS
MWS is a form of CAPS that is caused by is 
autosomal dominant genetic mutations on the NLRP3 
gene. Most families with CAPS have FCAS or MWS 
and affected individuals of the family frequently share 
common symptoms. People with MWS have been able 
to have children which have led to the syndrome being 
present in some families for many generations. Chronic 
and recurrent hives on the entire body are present 
during early childhood. Fevers start in early childhood 
and are related to flare-ups of symptoms like rashes, 
joint pains, headaches, and eye inflammation. These 
symptoms usually last 1–2 days and can be activated 
sometimes by cold temperatures, stress, or exercise.
Joint pains are not associated with tissue and 
cartilage damage. Recurrent conjunctivitis is often a problem 
with MWS, and many patients also have a haze on their 
corneas. Hearing loss occurs in most patients during early 
adolescence. Due to chronic high levels of inflammation, 
some patients with MWS may develop amyloidosis, with 
presence of amyloid within the kidneys and liver [12], [13].
At present, the best medications found to help that 
the many sufferers of MWS have been the use of different 
IL-1ß blocking drugs to prevent the cellular uptake of IL-1ß.
NOMID/CINCA
NOMID/CINCA has the highest seriousness of 
chronic inflammation of all the forms of CAPS. It is also 
caused by mutations in the same genetic region of the 
NLRP3 gene. NOMID/CINCA symptoms are present 
at birth, or shortly after, with the hives rash which can 
increase during times of flare-ups of inflammation, 
fevers, pain in the joints, headaches, red eyes, and 
other symptoms. Swelling of the joints is sometimes 
with changes to the growth cartilage. Central nervous 
system symptoms may include headaches, stiffness of 
the neck and nausea, elevated spinal fluid pressures, 
chronic aseptic meningitis with elevated neutrophils, 
and eosinophils present in the cerebrospinal fluid. The 
majority of children have significant mental deficits. 
During inflammatory episodes, many people with 
NOMID/CINCA and other forms of CAPS can suffer 
from conjunctivitis which is not caused by infection, 
they also have chronic papilledema within the eyes 
which can lead to a serious loss of vision. Progressive 
deafness can occur in these patients in early childhood. 
Some patients have dysmorphical facial characteristics, 
such as a saddleback nose or frontal bossing, smaller 
teeth, and other dental anomalies. There is a significant 
risk for amyloidosis with elevated serum amyloid and 
kidney damage, and some patients also have enlarged 
liver and spleen [14], [15]. Treatment has been the use 
of various IL-1ß-blocking drugs.
The main clinical characteristics of CAPS are 
presented in Table 1.
Table 1: Clinical characteristics of CAPS
Familial cold urticaria Muckle-wells syndrome Neonatal-Onset multisystem 
inflammatory disease
Triggered by cold Sometimes triggered by 
cold
Not triggered by cold
Recurrent fever Recurrent fever Persistent fever
Hives Hives Hives
Arthralgia Arthritis Arthritis/joints damage
Conjunctivitis Conjunctivitis, episcleritis, 
uveitis
Conjunctivitis, episcleritis, uveitis, 
optic atrophy
Hearing loss Hearing loss
Amyloidosis Amyloidosis
Headaches Chronic aseptic meningitis
Diagnostic Procedures for Caps
During acute attacks laboratory tests often 
reveal signs of non-specific inflammatory markers, 
such as elevated erythrocyte sedimentation rate (ESR), 
high C-reactive protein (CRP), anemia, leukocytosis 
with a high number of polynuclear leukocytes and 
thrombocytes, and elevated serum amyloid A (SAA) 
(in MWS and NOMID/CINCA). In the case of NOMID/
CINCA, lumbar punction shows cerebrospinal fluid at 
high pressure with neutrophils and eosinophils and 
no infection, while blood elements are rarely present 
in MWS. The following tests may also be performed: 
Audiogram which shows high-frequency hearing loss, 
progressing to bilateral deafness, urinary protein to 
detect amyloidosis, and kidney biopsy to confirm the 
presence of amyloid deposits. Genetic testing can be 
performed using a commercial test for an NLRP3 gene 
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mutation and should be done for all patients suspected 
to have CAPS, but should not be the only basis of 
diagnosis.
Treatment
Medications for CAPS target the main source 
of inflammation which is the over-production of IL 1ß 
by altered cryopyrin inflammasomes. Three drugs that 
target IL-1 are approved by the US Food and Drug 
Administration for the treatment of CAPS. The short-
acting recombinant IL-1 receptor antagonist named 
anakinra was approved for the treatment of patients 
with NOMID in 2012, and the two long-acting IL-1-
blocking agents, rilonacept, and canakinumab were 
approved for the treatment of CAPS in 2008 and 2009.
Anakirna is a recombinant and non-
glycosylated synthetic form of human IL-1ß receptor 
antagonist (Il-1 Ra) and acts like the endogenous 
human Il-1RA to inhibit Il-1ß binding to the Il-1receptor 
type1 (Il-1 RI), which helps to inhibit the biologic activity 
of Il-1ß in the body. The drug is administered as a daily 
subcutaneous injection. Rilonacept is an IL-1ß (IL-1ß) 
blocking medication that inhibits IL-1ß by attaching 
and neutralizing IL-1ß in the circulating blood. This can 
prevent the cells from being triggered to activate the 
increase production of inflammatory mediators and is 
given as a weekly subcutaneous injection. Canakinumab 
is a fully-humanized monoclonal antibody against IL-1ß 
with affinity for human solubile IL-1ß. It is given every 
4–8 weeks by subcutaneous injection.
The goals of therapy in CAPS are (a) to improve 
the disease symptoms, to reduce the attack frequency 
and duration, (b) to diminish the systemic inflammatory 
markers in the blood as CRP, ESR, and SAA, and (c) to 
prevent progression of organ damage.
Caps Treatment-clinical Studies
Clinical studies assessing the efficacy 
of anakinra and later studies with the other IL-1-
blocking agents show significant improvement in the 
clinical symptoms of CAPS and also improvement in 
inflammatory markers.
The efficacy of the anakinra has been assessed 
in case reports [16], as well as several clinical studies. 
The study on 26 NOMID patients observed for 36–60 
months find clinical and laboratory response achieved 
and sustained in all patients [17]. The study of 12 patients 
with MWS phenotype up to 14 months on anakinra 
reported that all patients had a significant improvement 
at 2 weeks and at the final follow-up. Treatment induced 
complete and long-lasting resolution of fever, arthralgia/
arthritis, and improvement of conjunctivitis at 2 weeks 
in all patients. Skin rash resolved in 7 of 8 patients. 
Amyloidosis improved in 1of the 2 patients with 
confirmed amyloidosis. Hearing loss resolved in 1 and 
improved in 1of 10 individual. Hearing loss worsened in 
two patients under treatment [18]. Studies in patients 
with NOMID showed that treatment with anakinra can 
invert organ inflammation such as aseptic meningitis, 
papilledema, and cochlear inflammation [19]. Rilonacept 
was better than to placebo in improving the primary 
(composite symptom score) and secondary (flare days, 
single-symptom scores, and disease activity) points 
in a 24-week study of 47 patients with MWS or FCAS 
phenotypes [20]. Rilonacept showed improved clinical 
symptoms induced by cold within days of administration 
in five patients with observed during 24 months 
follow-up [11]. Canakinumab achieved complete 
response in the open-label phase of a 48-week study 
of 31 patients with MWS and four patients with NOMID. 
In the randomized phase, 81% of the patients in the 
placebo group relapsed, whereas all patients in the 
drug group remained in remission [21].
The doses of IL-1-blocking therapy are 
needed to suppress systemic and organ inflammation 
depend on disease severity and the extent of organ 
involvement. For anakinra, higher doses up to 10 mg/
kg/day [19] have been used, and higher dosing has 
been investigated for patients with more serious forms 
of CAPS.
Prognosis
With suitable medications, most of the patients 
with FCAS and MWS can have normal life, get married, 
and have children. NOMID/CINCA patients have 
more severe form of inflammation through their body 
which can cause some permanent damage. If early 
diagnosis and treatment with medications are started, 
the prognosis is greatly improved, with most patients 
surviving into adulthood.
Conclusion
CAPS is a growing family of autoinflammatory 
diseases, also known as periodic fever syndromes. 
CAPS is caused by genetic mutations in the NLRP3 
gene that regulates the innate immune response 
which results in a hyperactive cryopyrin protein and 
an increased inflammatory response, leading to 
overproduction of pro-inflammatory cytokine IL-1ß. 
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These changes result in episodes of fever and damage 
to the body’s cells and tissues. The foremost common 
findings between all the CAPS disorders are rash, fever 
which is sometimes present at birth or in early childhood, 
joint problems, and conjunctivitis. More extreme forms 
of CAPS include more persistent inflammation that can 
cause hearing loss, meningitis and can lead to mental 
and developmental delays.
With medications that target the main source 
of inflammation which is the over-production of IL 1ß, 
anakinra, rilonacept, and canakinumab, prognosis is 
greatly improved, with most patients having less frequent 
episodes of the disease, preventing amyloidosis, and 
for severe cases – surviving into adulthood.
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